Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Methods of treating ocular diseases

A disease, program technology, applied in the field of treatment of eye diseases

Pending Publication Date: 2022-04-19
NOVARTIS AG
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Diabetic macular edema (DME) can occur at any stage of DR but is more likely to manifest after severe nPDR and PDR

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating ocular diseases
  • Methods of treating ocular diseases
  • Methods of treating ocular diseases

Examples

Experimental program
Comparison scheme
Effect test

example

[0173] A clinical study was designed to evaluate the efficacy and safety of brucetizumab in patients with proliferative diabetic retinopathy (PDR), specifically compared to panretinal photocoagulation (PRP) laser efficacy and safety.

[0174] This study was a 96-week, two-arm, randomized, single-blinded, multicenter, active-controlled, non-inferiority study in patients with proliferative diabetic retinopathy (PDR).

[0175] Consenting patients will undergo a screening assessment to assess eligibility based on certain inclusion and exclusion criteria. Subjects who meet all the inclusion criteria without any exclusion criteria will be randomly assigned 1:1:

[0176] Buxacizumab 6 mg: 3x q6w loading over 90 weeks followed by q12w maintenance with the option to extend the treatment interval by 6 weeks at a time starting at week 48 up to a maximum of 24 weeks.

[0177] PRP: Initial treatment in 1-3 courses for up to 12 weeks, followed by additional PRP treatments as needed for up...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

A method of treating a patient having a neovascular ocular disease is provided.

Description

[0001] sequence listing [0002] This application contains a Sequence Listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy was created on July 28, 2020 and is named PAT058689_SEQ_LISTING_ST25.txt and is 8KB in size. technical field [0003] The present invention relates to methods of treating ocular disorders with VEGF antagonists. In particular, the present invention relates to the treatment of neovascular ocular diseases, such as diabetic retinopathy and proliferative diabetic retinopathy, with less frequent dosing than currently licensed treatment regimens. Background technique [0004] Diabetes mellitus (DM) is the most common endocrine disorder in developed countries, with prevalence estimated to be between 2% and 5% of the world's population. Diabetic retinopathy (DR) and diabetic macular edema (DME) are common microvascular complications in diabetic patients and may have the effect of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395C07K16/22A61P9/10A61P27/02
CPCA61K39/3955A61K9/0048A61K9/0019A61P27/02A61P9/10C07K16/22C07K2317/24A61K2039/505A61K2039/545C07K2317/622C07K2317/76A61K2039/54
Inventor P·M·C·马尔加罗M·格基瓦
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com